Introduction
============

Lower-limb venous insufficiency is common in adults and can manifest as a cosmetic annoyance in the early stages, but advance to a debilitating condition[@b1]. Signs and symptoms include visible varicose veins, calf pain or swelling, leg cramping or fatigue, and a sensation of heaviness[@b1]. Left untreated, skin discoloration, induration or active ulceration may ensue. Most frequently, incompetent valves in the great or small saphenous veins cause pathological venous reflux, and precipitate this condition[@b1],[@b2]. When a refluxing saphenous vein is diagnosed, removing it from the circulation eliminates or improves the associated signs and symptoms.

Traditionally, high saphenous ligation and stripping (HLS) surgery has been used to remove the diseased great saphenous vein (GSV). Although successful, its invasive nature is associated with postoperative morbidity and delay in return to normal activities[@b3]--[@b5]. Less invasive endovascular treatments have been developed with the goal of achieving equal or better efficacy than HLS surgery, with reduced postoperative morbidity and faster recovery[@b6],[@b7]. Radiofrequency segmental thermal ablation (RFA) is a technique used for heat-induced obliteration of incompetent truncal veins, with excellent early results, including high ablation rates, moderate side-effects and speedy return to normal activities[@b8]--[@b10]. Short- and mid-term results from prospective randomized trials[@b11]--[@b13] and a meta-analysis[@b14] comparing RFA with HLS, endovenous laser or ultrasound-guided foam sclerotherapy proved that RFA sets the standard in terms of efficacy and safety.

This report presents the 5-year final results of the European multicentre cohort study including first-in-human use of RFA.

Methods
=======

This international, prospective, multicentre, cohort study was designed to evaluate the long-term effects of RFA of the GSV using a catheter with an integrated heating element, the ClosureFast™ (Venefit™; Covidien, Mansfield, Massachusetts, USA) procedure. Unselected, consecutively screened patients presenting with signs and symptoms of lower-limb venous disease in the GSV with confirmed reflux, defined as reverse flow with duration greater than 0·5 s on duplex ultrasound imaging (DUS), and eligible for endovascular treatment, were candidates for the study. Inclusion criteria also included age between 18 and 80 years at time of enrolment, physical condition allowing frequent walking after the procedure, and availability to complete study requirements. Patients who had thrombosis in the diseased vein segment to be treated, were pregnant, had a known allergic reaction to required anaesthetics, or were participating in another clinical trial were excluded from the study[@b10].

Eight sites in Germany and France participated in the study. All investigators had experience with the previous ClosurePlus™ catheter (Covidien) and were trained on the study device before participation. The study protocol was approved by the local ethical review boards; all subjects provided written informed consent. Study visits took place at baseline, time of the procedure, and 1 week, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years after the procedure. Follow-up visits included clinical and DUS evaluations. This trial is registered at <http://ClinicalTrials.gov> (NCT00842296).

Procedures
----------

A detailed description of the study protocol was published previously[@b10]. Briefly, the study device, the ClosureFast™ catheter, is a 7-Fr catheter with an integrated heating element and handle with an attached cable for connection to the radiofrequency generator. The catheter is compatible with 0·025-inch guidewires, and available in lengths of 60 and 100 cm. The distal heating element is 7 cm long. It comprises a fixed-diameter heating coil element that transfers heat to the vessel wall by contact and conduction with the vessel wall tissue. The heating element is activated with radiofrequency energy to 120°C for 20-s heating cycles. For study procedures, the vein was accessed at the distal point of reflux, and the catheter tip was advanced towards the epigastric vein connection and placed 1--2 cm below the saphenofemoral junction (SFJ). Energy was delivered after injection of perivenous tumescent local anaesthesia, as described previously[@b10]. External compression was achieved during treatment either manually or by using the ultrasound probe. If applicable, patients were offered treatment of tributaries by either phlebectomy or sclerotherapy at the discretion of the treating physician.

At each follow-up visit, DUS was completed to assess vein occlusion, reflux status (if flow was present) and compressibility of the treated segment, and for measurement of the diameters of the treated vein segment. Ultrasound examinations were performed by a physician familiar with the procedure to obtain ultrasound information on the treated leg at the same level. Follow-up clinical evaluation included assessment of venous signs and symptoms, return to normal activity, walking status and adverse events.

Endpoints
---------

The primary study endpoints were vein occlusion and absence of reflux, as determined by DUS. Vein occlusion was defined as absence of flow in the treated vein using distal augmentation. Flow in the stump of the GSV up to 3 cm below the SFJ was considered normal. Secondary endpoints were evaluated using standard scales, including the Clinical Etiologic Anatomic Pathophysiologic (CEAP) classification[@b15],[@b16], the Venous Clinical Severity Score (VCSS)[@b17],[@b18], and a visual analogue scale for pain, to assess clinical signs and symptoms of lower-limb venous disease, and patient interviews for presence of complications and side-effects.

Statistical analysis
--------------------

All legs of enrolled patients with available data were considered analysable. The primary endpoints are presented over 5 years using Kaplan--Meier estimates. CEAP was analysed as an ordinal variable, VCSS as a continuous variable using both parametric and non-parametric tests, and pain as a continuous variable using parametric tests. All statistical analyses were performed using SAS® (SAS Institute, Cary, North Carolina, USA).

Results
=======

Between April 2006 and March 2007, 225 subjects were enrolled and 295 legs (bilateral disease in 70 patients) were treated at eight centres in Germany and France. At 5 years, 177 subjects with 236 treated limbs had completed the follow-up examinations; the study completion rate was 78·7 per cent. Baseline characteristics of the study subjects and procedural data have been published in detail elsewhere[@b9].

The mean(s.d.) preoperative diameter of all study-treated GSVs 3 cm distal to the SFJ (GSV-3 cm) was 5·8(2·2) (range 2·0--18·0) mm. The majority of vein diameters were measured in the supine position (222, 75·3 per cent), based on the guidance provided in the initial version of the study protocol, with a mean baseline diameter of 5·5(2·3) (2·0--18·0) mm. In comparison, the GSV-3 cm diameters measured in the standing position (73 legs) were significantly larger: mean 6·9(1·8) (2·5--11·8) mm (*P* \< 0·001). Previous venous procedures on the treated leg included sclerotherapy (5·4 per cent), phlebectomy (2·7 per cent), stripping (1·0 per cent), VNUS ClosurePlus™ catheter (0·7 per cent), endovascular laser (0·3 per cent), ligation (0·3 per cent) and other (0·3 per cent).

Early results
-------------

Technical success was achieved in all legs (295, 100 per cent). The mean GSV-3 cm diameter immediately after the procedure as measured by DUS (291 legs) was 3·3(1·5) (0·8--9·2) mm, in comparison with 5·8(2·2) (2·0--18·0) mm before the procedure. Vein wall thickening was visible in the treated segment in 293 (99·7 per cent) of 294 legs. Vein occlusion immediately after segmental thermal ablation was achieved in 294 legs (99·7 per cent), with a mean distance from the SFJ to the occlusion of 1·1(0·5) (0--2·9) cm. The remaining leg had delayed GSV occlusion, shown at 1 week after study treatment.

Ultrasound follow-up
--------------------

DUS was performed during follow-up visits to measure vein diameters following segmental thermal ablation therapy. Compliance with the DUS follow-up was 98·3 per cent at 3 months, 98·0 per cent at 6 months, 99·0 per cent at 1 year, 94·6 per cent at 2 years, 88·1 per cent at 3 years, 86·1 per cent at 4 years and 80·0 per cent at 5 years. Mean diameters of the GSV-derived fibrotic cord 3 cm distal to the SFJ decreased from 5·8(2·2) mm before treatment to 4·6(1·7) mm at 1 week after treatment (295 legs) and 2·0(1·0) mm at 5 years (110 legs; 126 veins (53·4 per cent) not visible on DUS) (*Fig*. [1](#fig01){ref-type="fig"}). Mean stump lengths at the SFJ remained stable over time: 1·0(0·7) cm at 1 week (289 legs), 1·2(0·7) cm at 3 months (289 legs) and 1·4(1·5) cm at 5 years (233 legs) after treatment.
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Blood flow in any part of the treated GSV from 3 cm below the SFJ and distally was observed in 25 different GSVs during follow-up. Of these, 15 legs had GSV reflux, which, remarkably, was not necessarily linked to clinical symptoms. Of the 15 legs, clinically significant total recanalization of the treated GSV was observed in three (at 1 week, 6 months and 3 years). Segmental recanalization was noted in the other 12 legs, with reflux originating at the SFJ in ten (1 at 3 months, 2 at 1 year, 3 at 2 years, 2 at 3 years, 2 at 4 years) and reflux not connected to the SFJ in two legs (1 at 2 years, 1 at 3 years). For the ten legs with reflux originating at the SFJ, the mean length of the patent segment was only 5·8 (3·2--10) cm. Four of the ten legs were completely asymptomatic; the other six had recurrent varicose veins.

For the two legs with reflux not originating at the SFJ, reflux was observed in the distal third of the GSV, originating from a tributary in one patient, and at mid-GSV with reflux originating from a perforating vein in the second patient. Both legs had multiple varicose veins above and below the knee.

Among the 15 legs with documented reflux during follow-up, two had a patent segment at 1 and 2 years, and presented with reflux 1 year later. In contrast, the reflux observed in one leg at 3 months and in two legs at 2 years was no longer present at 1 and 5 years respectively.

Ten other legs developed a patent segment of the treated GSV without reflux on DUS. In nine, the patent segment originated from the SFJ with a mean length of only 4·1 (3·3--6·5) cm, and had no clinical relevance. In one leg, the patent segment free from reflux was located below the knee.

Using Kaplan--Meier estimates, the GSV occlusion rate was 91·9 per cent at 5 years (*Fig.* [2](#fig02){ref-type="fig"}). The Kaplan--Meier estimate of reflux-free GSV was 94·9 per cent at 5 years (*Fig. S1*, supporting information). The standard errors for all estimates were below 2 per cent.
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Clinical results
----------------

At baseline, the mean VCSS for the 295 legs was 3·9(2·1), ranging from 1, representing uncomplicated varicose veins or venous oedema with ankle swelling in the evening, to 11, in a patient with ankle ulceration. The VCSS improved over time starting 3 months after RFA, reaching a value of 1·3(1·7) for 236 treated legs at the 5-year follow-up (*Fig*. [3](#fig03){ref-type="fig"}).
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Varicose veins were present in 98·6 per cent of legs at baseline, with 52·2 originating from the GSV (VCSS domain score 2). At 3 months after treatment, only 15·2 per cent of the treated limbs had varicose veins present, according to the VCSS assessment. The proportion of legs with varicose veins (VCSS domain score 1) increased over time to 40·7 per cent at 5 years. However, at the same time, only 5·9 per cent of the treated legs had multiple varicose veins originating from the GSV (VCSS domain score 2) (*Fig. S2*, supporting information).

Similarly, 52·9 per cent of diseased limbs had oedema at baseline. By 3 months after treatment, only 8·6 per cent of the treated legs had residual oedema, but this increased to 23·7 per cent by 5 years, according to the VCSS assessment. At 5 years, most of the reported residual oedema was at the ankles and visible only in the evenings (19·1 per cent; VCSS domain score 1). A few patients also had oedema below the knee visible in the afternoon (VCSS domain score 2; 1·7 per cent at 1 year, 2·7 per cent at 3 years, 4·2 per cent at 5 years) (*Fig. S3*, supporting information).

Significant pain was present in the legs at baseline in 58·6 per cent of the legs, according to the VCSS pain domain: occasional (39·0 per cent), daily (17·3 per cent) or activity-limiting (2·4 per cent). By 3 months after treatment, this had decreased to 6·9 per cent of legs: occasional (5·5 per cent) or daily (1·4 per cent). According to the VCSS assessment, 92·4 per cent of the treated limbs were pain-free at the 5-year follow-up visit (*Fig. S4*, supporting information).

Discussion
==========

Here, the 5-year results of the first-in-human use of segmental thermal ablation for incompetent GSVs are reported. The strength of this prospective multicentre cohort study arises from the high compliance rate of 80·0 per cent for DUS after 5 years[@b19]. Meanwhile, studies on RFA with shorter follow-up have already proven the high efficacy, safety and speed of the procedure[@b8],[@b9],[@b12],[@b13]. Its favourable side-effect profile, in conjunction with a high rate of maintained GSV occlusion in the mid-term[@b9], have been corroborated by prospective multicentre comparisons with endovenous laser and surgery[@b13]. Other studies[@b11],[@b12] have confirmed the favourable side-effect profile of RFA in comparison with endovenous laser ablation (EVLA). Pain, tenderness and bruising were less frequent after RFA during the first 2 weeks after the procedure[@b11], and patients who received RFA returned to work 4 days earlier than those who received EVLA[@b12]. Looking at other relevant side-effects, the rate of paraesthesia of 0·4 per cent in the present study[@b9] compared favourably with a rate of 7·6 per cent 12 months after EVLA, performed with a more recently used wavelength of 1470 nm[@b20]. Comparing RFA with the new technique of mechanochemical ablation (MOCA), it seems that MOCA is less painful with a quicker return to work; however, MOCA has not yet proven equal to RFA for clinical and anatomical outcomes at 1-year follow-up[@b21].

RFA maintains occlusion rates of more than 90 per cent and freedom from reflux in 95 per cent of legs after 5 years. This is reassuring with such a favourable side-effect profile. Currently, the focus of most new treatments for saphenous vein reflux is directed towards a minimal side-effect profile and high periprocedural quality of life. However, the primary intention of reliable and durable abolition of vein reflux must not be sacrificed. Foam sclerotherapy of saphenous veins, which initially looks attractive because of its easy and quick delivery and its minimal impairment of quality of life, serves as an example. With a side-effect and quality-of-life profile comparable to RFA[@b13], 1-year anatomical success rates of between 70 per cent[@b22] and 75 per cent[@b23] after foam sclerotherapy are lower than those obtained with endothermal technology. Foam sclerotherapy should be questioned as a first-line therapy for refluxing saphenous veins, especially for large veins, as the risk of failure increases when the diameter of the vein is 6 mm or more[@b24],[@b25]. In this context, anatomical long-term results of MOCA are still lacking. Similarly, adapted protocols for delivery of endovenous laser with lowered energy doses have to be examined critically. With a reduction in laser energy dose, side-effect profiles can be ameliorated, but anatomical success rates may drop below the standard benchmarks[@b26].

The definition of occlusion in the present study was very restrictive: complete occlusion with absence of any reflux along the treated vein up to 3 cm below the SFJ. Even in 14 of 25 non-occluded veins, the patent part of the GSV was 5 cm or less. In such instances true failure of the treatment is questionable because the distribution of the venous tributaries can influence the final length of the patent GSV[@b27].

Although quality of life was not assessed in the present study, the VCSS and some of its subdomains clearly indicated the achievement of durable clinical success after RFA. Throughout the 5-year follow-up, the VCSS remained significantly improved, with maintenance of low scores. According to the VCSS assessment, presence of varicose veins (component score 1--3) dropped to a minimum of less than 5 per cent at 6-week follow-up, but constantly increased thereafter to 47·4 per cent at 5 years, reflecting the natural course of venous disease. Most dramatically, the VCSS pain domain improved in a durable way; at baseline only 41·4 per cent of the affected legs were free from pain, whereas this proportion stayed above 90 per cent throughout 5-year follow-up.

RFA is an effective and durable treatment for great saphenous varicose veins. Comprehensive follow-up for other methods to 5 years is required to establish the optimal treatment for varicose veins.
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